Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allient Inc. stock logo
ALNT
Allient
$35.88
+3.7%
$28.70
$16.91
$36.08
$585.91M1.47116,878 shs131,520 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$9.18
+10.9%
$7.07
$3.91
$13.99
$569.76M1.61812,807 shs848,290 shs
908 Devices Inc. stock logo
MASS
908 Devices
$6.62
-0.3%
$5.82
$1.81
$8.06
$238.12M0.291.04 million shs388,514 shs
Transcat, Inc. stock logo
TRNS
Transcat
$83.15
+3.6%
$82.59
$67.56
$147.12
$747.93M0.7587,650 shs59,992 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allient Inc. stock logo
ALNT
Allient
+3.67%+4.73%+20.08%+53.60%+42.10%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
+10.87%+4.20%+61.62%+51.49%+7.75%
908 Devices Inc. stock logo
MASS
908 Devices
-0.30%-9.93%+37.92%+63.46%+26.58%
Transcat, Inc. stock logo
TRNS
Transcat
+3.59%+3.73%-8.95%+15.73%-30.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allient Inc. stock logo
ALNT
Allient
1.6336 of 5 stars
1.33.01.70.00.62.51.9
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
2.0655 of 5 stars
3.52.00.00.02.41.70.0
908 Devices Inc. stock logo
MASS
908 Devices
2.1564 of 5 stars
1.34.00.00.02.95.00.6
Transcat, Inc. stock logo
TRNS
Transcat
2.9079 of 5 stars
3.33.00.00.02.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allient Inc. stock logo
ALNT
Allient
2.50
Moderate Buy$31.00-13.60% Downside
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3.00
Buy$25.67179.59% Upside
908 Devices Inc. stock logo
MASS
908 Devices
2.50
Moderate Buy$5.33-19.44% Downside
Transcat, Inc. stock logo
TRNS
Transcat
2.50
Moderate Buy$114.0037.10% Upside

Current Analyst Ratings Breakdown

Latest MASS, TRNS, EYPT, and ALNT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$28.00
6/11/2025
908 Devices Inc. stock logo
MASS
908 Devices
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
5/29/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/24/2025
908 Devices Inc. stock logo
MASS
908 Devices
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
5/21/2025
Transcat, Inc. stock logo
TRNS
Transcat
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$106.00 ➝ $116.00
5/16/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/10/2025
908 Devices Inc. stock logo
MASS
908 Devices
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
5/8/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$33.00 ➝ $27.00
5/5/2025
Allient Inc. stock logo
ALNT
Allient
Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$35.00
5/5/2025
Allient Inc. stock logo
ALNT
Allient
Northland Capmk
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/5/2025
Allient Inc. stock logo
ALNT
Allient
Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allient Inc. stock logo
ALNT
Allient
$529.97M1.15$3.14 per share11.41$15.72 per share2.28
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$43.27M14.60N/AN/A$4.93 per share1.86
908 Devices Inc. stock logo
MASS
908 Devices
$59.63M3.98N/AN/A$3.29 per share2.01
Transcat, Inc. stock logo
TRNS
Transcat
$278.42M2.78$4.42 per share18.81$30.82 per share2.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allient Inc. stock logo
ALNT
Allient
$13.17M$0.5960.8119.61N/A1.90%8.45%3.86%8/6/2025 (Estimated)
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$130.87M-$2.41N/AN/AN/A-261.91%-54.27%-41.75%8/6/2025 (Estimated)
908 Devices Inc. stock logo
MASS
908 Devices
-$72.21M-$0.54N/AN/AN/A-28.80%-27.10%-20.49%8/5/2025 (Estimated)
Transcat, Inc. stock logo
TRNS
Transcat
$14.52M$1.5653.3031.62N/A5.21%6.47%5.02%8/4/2025 (Estimated)

Latest MASS, TRNS, EYPT, and ALNT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q4 2025
Transcat, Inc. stock logo
TRNS
Transcat
$0.66$0.64-$0.02$0.48$76.40 million$77.13 million
5/13/2025Q1 2025
908 Devices Inc. stock logo
MASS
908 Devices
-$0.27-$0.22+$0.05$1.23$11.90 million$11.78 million
5/7/2025Q1 2025
Allient Inc. stock logo
ALNT
Allient
$0.33$0.46+$0.13$0.21$125.00 million$134.62 million
5/7/2025Q1 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allient Inc. stock logo
ALNT
Allient
$0.120.33%N/A20.34%N/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
908 Devices Inc. stock logo
MASS
908 Devices
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A

Latest MASS, TRNS, EYPT, and ALNT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/7/2025
Allient Inc. stock logo
ALNT
Allient
quarterly$0.030.4%5/22/20255/22/20256/5/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allient Inc. stock logo
ALNT
Allient
0.81
4.03
2.35
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
7.85
7.79
908 Devices Inc. stock logo
MASS
908 Devices
N/A
7.62
6.97
Transcat, Inc. stock logo
TRNS
Transcat
0.11
2.29
1.87

Institutional Ownership

CompanyInstitutional Ownership
Allient Inc. stock logo
ALNT
Allient
61.57%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
908 Devices Inc. stock logo
MASS
908 Devices
88.06%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%

Insider Ownership

CompanyInsider Ownership
Allient Inc. stock logo
ALNT
Allient
14.90%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
4.46%
908 Devices Inc. stock logo
MASS
908 Devices
23.70%
Transcat, Inc. stock logo
TRNS
Transcat
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allient Inc. stock logo
ALNT
Allient
2,52516.93 million14.41 millionOptionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12068.81 million65.74 millionOptionable
908 Devices Inc. stock logo
MASS
908 Devices
6035.86 million27.36 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
1,2459.32 million9.10 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Allient stock logo

Allient NASDAQ:ALNT

$35.88 +1.27 (+3.67%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$35.94 +0.06 (+0.18%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allient Inc., together with its subsidiaries, designs, manufactures, and sells precision and specialty controlled motion components and systems for various industries in the United States, Canada, South America, Europe, and Asia-Pacific. It offers brush and brushless DC motors, brushless servo and torque motors, coreless DC motors, integrated brushless motor-drives, gearmotors, gearing, modular digital servo drives, motion controllers, optical encoders, active and passive filters, input/output modules, industrial communications gateways, light-weighting technologies, and other controlled motion-related products, as well as nano precision positioning systems, servo control systems, and digital servo amplifiers and drives. The company sells its products to end customers and original equipment manufacturers in vehicle, medical, aerospace and defense, and industrial markets through direct sales force, authorized manufacturers' representatives, and distributors. The company was formerly known as Allied Motion Technologies Inc. and changed its name to Allient Inc. in August 2023. Allient Inc. was incorporated in 1962 and is headquartered in Amherst, New York.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$9.18 +0.90 (+10.87%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$8.89 -0.29 (-3.16%)
As of 08:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

908 Devices stock logo

908 Devices NASDAQ:MASS

$6.62 -0.02 (-0.30%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$6.48 -0.15 (-2.19%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Transcat stock logo

Transcat NASDAQ:TRNS

$83.15 +2.88 (+3.59%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$83.18 +0.03 (+0.04%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.